計劃書編號FB825CLRS02
試驗執行中
2024-01-01 - 2026-12-31
Phase II
尚未開始2
召募中8
ICD-10L22
尿布疹
ICD-9691.0
尿布疹
一項多中心、隨機、雙盲、安慰劑對照，評估FB825重複劑量皮下注射在中度至重度之異位性皮膚炎成人患者的療效、藥物動力學和安全性試驗
-
試驗申請者
合一生技股份有限公司
-
試驗委託 / 贊助單位名稱
合一生技股份有限公司
-
臨床試驗規模
多國多中心
-
更新日期
2026/02/01
試驗主持人及試驗醫院
實際收案人數
0 召募中
實際收案人數
0 召募中
實際收案人數
0 尚未開始
實際收案人數
0 召募中
實際收案人數
0 召募中
實際收案人數
0 召募中
適應症
中度至重度之異位性皮膚炎
試驗目的
主要目的:
•評估FB825重複劑量皮下注射在中重度之異位性皮膚炎成人患者基線異位性皮膚炎區域和嚴重程度指數Eczema Area and Severity Index (EASI)評分改善之功效。
次要目的:
•評估重複劑量皮下注射FB825對中重度之異位性皮炎成年患者的額外療效終點（vIGA-AD和SCORAD）以及患者報告的結果（NRS和DLQI）隨時間的改善功效。
•評估重複劑量皮下注射FB825在時間內對中重度之異位性皮炎成年患者的安全性和耐受性。
•評估重複劑量皮下注射FB825的藥代動力學特性。
探索性目的:
•探討在重複劑量皮下注射FB825後產生抗-FB825抗體的情況。
•評估治療過程中血清過敏原特異性IgG4（sIgG4）的水平。
•探討FB825對血清生物標誌物的藥效學效應。
•探討白血球細胞（WBC）在血液中的分類計數（百分比）的變化。
•探討週邊血單核細胞（PBMC）中mIgE RNA轉錄表達的變化。
•探討救援性外用局部皮質類固醇（TCS）的使用狀況。
藥品名稱
皮下注射劑
主成份
anti-CemX Ab
劑型
220
劑量
150 mg/mL
評估指標
The percentage change from baseline in EASI score at Week 16.
主要納入條件
1.The subject is male or female between 18 and 65 years of age at the time of giving informed consent.
2.Body weight equal to or greater than 40 Kg at the time of screening.
3.The subject has a physician-confirmed diagnosis of moderate-to-severe atopic dermatitis based on 12 months history of symptoms designated by Hanifin and Rajka criteria.
4.Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline visits.
5.Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3 (5-point scale) at the screening and baseline visits.
6.≥10 % body surface area (BSA) of AD involvement at the screening and baseline visits.
7.Baseline pruritus numerical rating scale (NRS) average score for maximum itch intensity of ≥ 3, based on the average of daily pruritus NRS scores for maximum itch intensity reported during the 7 days prior to randomization.
8.History of inadequate response to a stable (4 weeks) regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD within 6 months before the screening visit. (The TCS should belong to medium to high potency strength and has been applied for at least 4 weeks or for the maximum duration recommended by product prescribing information.)
•An inadequate response is defined as the inability to achieve and maintain remission or a low disease activity state (comparable to vIGA-AD 0=clear to 2=mild).
•Subjects with systemic treatment for AD in the past 6 months were also considered as inadequate responders to topical treatments.
9.Patients must be applying stable doses of an additive-free, basic bland emollient twice-daily for at least 1 week immediately before the baseline visit.
Note: See exclusion criterion #13 for limitations regarding emollients.
10.Female subjects must have a negative serum pregnancy test at screening. All subjects of childbearing potential and his/her sexual partner must meet 2 following codition or acceptable methods of birth control throughout the study.
•Oral, injectable, or implanted hormonal contraceptives
•Condom with a spermicidal form, gel, film, cream, or suppository
•Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal foam, gel, film,cream, or suppository
•Intrauterine device
•Intrauterine system (for example, progestin-releasing coil) or be surgically sterile (i.e., hysterectomy, bilateral tubal ligation, bilateral oophorectomy, or vasectomy)
•Postmenopausal (defined as amenorrhea 12 consecutive months and documented serum follicle stimulating hormone level per laboratory standard)
Note: The subject must utilize the method of effective contraception during study period as well as 16 weeks or 5 half-lives following the last dosing of FB825.
11.The subject is able to provide written informed consent.
12.The subject agrees to and is capable of adhering to scheduled visits, the treatment plan, laboratory tests, other study procedures, and all protocol requirements.
2.Body weight equal to or greater than 40 Kg at the time of screening.
3.The subject has a physician-confirmed diagnosis of moderate-to-severe atopic dermatitis based on 12 months history of symptoms designated by Hanifin and Rajka criteria.
4.Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline visits.
5.Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) score ≥ 3 (5-point scale) at the screening and baseline visits.
6.≥10 % body surface area (BSA) of AD involvement at the screening and baseline visits.
7.Baseline pruritus numerical rating scale (NRS) average score for maximum itch intensity of ≥ 3, based on the average of daily pruritus NRS scores for maximum itch intensity reported during the 7 days prior to randomization.
8.History of inadequate response to a stable (4 weeks) regimen of topical corticosteroids (TCS) or topical calcineurin inhibitors (TCI) as treatment for AD within 6 months before the screening visit. (The TCS should belong to medium to high potency strength and has been applied for at least 4 weeks or for the maximum duration recommended by product prescribing information.)
•An inadequate response is defined as the inability to achieve and maintain remission or a low disease activity state (comparable to vIGA-AD 0=clear to 2=mild).
•Subjects with systemic treatment for AD in the past 6 months were also considered as inadequate responders to topical treatments.
9.Patients must be applying stable doses of an additive-free, basic bland emollient twice-daily for at least 1 week immediately before the baseline visit.
Note: See exclusion criterion #13 for limitations regarding emollients.
10.Female subjects must have a negative serum pregnancy test at screening. All subjects of childbearing potential and his/her sexual partner must meet 2 following codition or acceptable methods of birth control throughout the study.
•Oral, injectable, or implanted hormonal contraceptives
•Condom with a spermicidal form, gel, film, cream, or suppository
•Occlusive cap (diaphragm or cervical/vault caps) with a spermicidal foam, gel, film,cream, or suppository
•Intrauterine device
•Intrauterine system (for example, progestin-releasing coil) or be surgically sterile (i.e., hysterectomy, bilateral tubal ligation, bilateral oophorectomy, or vasectomy)
•Postmenopausal (defined as amenorrhea 12 consecutive months and documented serum follicle stimulating hormone level per laboratory standard)
Note: The subject must utilize the method of effective contraception during study period as well as 16 weeks or 5 half-lives following the last dosing of FB825.
11.The subject is able to provide written informed consent.
12.The subject agrees to and is capable of adhering to scheduled visits, the treatment plan, laboratory tests, other study procedures, and all protocol requirements.
主要排除條件
1.Female subjects who are pregnant or lactating.
2.The subject with positive test results for HBeAg or HCV RNA should be excluded as they are indications of active hepatitis B virus and hepatitis C virus replication.
3.A positive human immunodeficiency virus (HIV) test (e.g., HIV Ag/Ab combo test) at screening or a history of HIV infection.
4.The subject has a history of alcohol or drug abuse within one year prior to screening that would impair or risk the patients’ full participation in the study, in the opinion of the investigator.
5.The subject has a clinically significant, currently active or severe gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory (with the exception of uncomplicated allergic rhinitis and allergic asthma), inflammatory, immunological, endocrine, diabetes, obesity [BMI≥35] or infectious disease and is ineligible to participate in the study as judged by the investigator.
6.The subject has a clinically significant history, as determined by the investigator, of drug allergies or hypersensitivity such as, but not limited to, sulfonamides and penicillin, or a drug allergy witnessed in a previous study with experimental drugs.
7.The subject has any history of a previous anaphylactic reaction.
8.The subject has any condition that, in the opinion of the investigator, would compromise the study or the well-being of the subject or prevent the subject from meeting or performing study requirements.
9.The subject has received TCS or TCI within 7 days prior to the baseline visit (Day 1).
10.The subject has received any immunoglobulin products or blood products within 3 months prior to baseline visit.
11.The subject has received a biologic product (including investigational biologic product) within 5 half-lives or 3 months, whichever is longer, before baseline visit.
12.The subject has received an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before baseline visit.
13.Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period.
14.Initiation of treatment of AD with sedative anti-histamine products during the screening period (patients may continue using stable doses of non-sedative anti-histamine).
15. The subject is a member of the professional or ancillary personnel involved in the study.
16.The subject regular use (≥2 visits per week) of a tanning booth/parlor within 4 weeks prior to the baseline visit.
17.The subject has received cell-based immunotherapy treatment within 3 months prior to baseline visit.
18.The subject has used any of the following classes of medication (prescription or over-the-counter) within specific time frames before the study drug treatment:
•Systemic corticosteroids within 4 weeks.
•Leukotriene modifiers within 4 weeks.
•Cyclosporine within 4 weeks, or other immunosuppressants (e.g. gold salts, methotrexate, azathioprine) within 4 weeks.
•IFN-γwithin 12 weeks, or other immunomodulating drugs within 4 weeks.
•Allergen immunotherapy within 1 year.
•JAK inhibitor within 4 weeks.
19.The subject has received phototherapy within 4 weeks before the study drug treatment.
20.The subject has received live vaccine within 12 weeks before the study drug treatment.
21.The subject has presence of skin comorbidities that may interfere with study assessments.
22.The subject has known or suspected history of immunosuppression, including history of opportunistic infections (e.g., TB) per investigator’s judgment.
23.The subject has active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit.
Note: Patients with resolved infection may be rescreened.
24.The subject has history of malignancy within 5 years before the screening period, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.
25.The subject has planned or anticipated the use of any prohibited medications and procedures during the entire study period.
26.The subject has planned or anticipated major surgical procedure during the entire study period.
27.High risk of parasite infection. Evidence of parasitic infection designated as having the following two items:
•Risk factors for parasitic disease include living in an endemic area, experiencing chronic gastrointestinal symptoms, traveling to regions where geohelminthic infections are endemic within the last 6 months, and/or having chronic immunosuppression).
AND
•Evidence of parasitic colonization or infection found during stool evaluation for ova and parasites.
Note: stool ova and parasite evaluation will only be conducted in patients with risk factors and an eosinophil count more than twice the upper limit of normal.
2.The subject with positive test results for HBeAg or HCV RNA should be excluded as they are indications of active hepatitis B virus and hepatitis C virus replication.
3.A positive human immunodeficiency virus (HIV) test (e.g., HIV Ag/Ab combo test) at screening or a history of HIV infection.
4.The subject has a history of alcohol or drug abuse within one year prior to screening that would impair or risk the patients’ full participation in the study, in the opinion of the investigator.
5.The subject has a clinically significant, currently active or severe gastrointestinal, cardiovascular, nervous system, psychiatric, metabolic, renal, hepatic, respiratory (with the exception of uncomplicated allergic rhinitis and allergic asthma), inflammatory, immunological, endocrine, diabetes, obesity [BMI≥35] or infectious disease and is ineligible to participate in the study as judged by the investigator.
6.The subject has a clinically significant history, as determined by the investigator, of drug allergies or hypersensitivity such as, but not limited to, sulfonamides and penicillin, or a drug allergy witnessed in a previous study with experimental drugs.
7.The subject has any history of a previous anaphylactic reaction.
8.The subject has any condition that, in the opinion of the investigator, would compromise the study or the well-being of the subject or prevent the subject from meeting or performing study requirements.
9.The subject has received TCS or TCI within 7 days prior to the baseline visit (Day 1).
10.The subject has received any immunoglobulin products or blood products within 3 months prior to baseline visit.
11.The subject has received a biologic product (including investigational biologic product) within 5 half-lives or 3 months, whichever is longer, before baseline visit.
12.The subject has received an investigational drug within 8 weeks or within 5 half-lives (if known), whichever is longer, before baseline visit.
13.Initiation of treatment of AD with prescription moisturizers or moisturizers containing additives such as ceramide, hyaluronic acid, urea, or filaggrin degradation products during the screening period.
14.Initiation of treatment of AD with sedative anti-histamine products during the screening period (patients may continue using stable doses of non-sedative anti-histamine).
15. The subject is a member of the professional or ancillary personnel involved in the study.
16.The subject regular use (≥2 visits per week) of a tanning booth/parlor within 4 weeks prior to the baseline visit.
17.The subject has received cell-based immunotherapy treatment within 3 months prior to baseline visit.
18.The subject has used any of the following classes of medication (prescription or over-the-counter) within specific time frames before the study drug treatment:
•Systemic corticosteroids within 4 weeks.
•Leukotriene modifiers within 4 weeks.
•Cyclosporine within 4 weeks, or other immunosuppressants (e.g. gold salts, methotrexate, azathioprine) within 4 weeks.
•IFN-γwithin 12 weeks, or other immunomodulating drugs within 4 weeks.
•Allergen immunotherapy within 1 year.
•JAK inhibitor within 4 weeks.
19.The subject has received phototherapy within 4 weeks before the study drug treatment.
20.The subject has received live vaccine within 12 weeks before the study drug treatment.
21.The subject has presence of skin comorbidities that may interfere with study assessments.
22.The subject has known or suspected history of immunosuppression, including history of opportunistic infections (e.g., TB) per investigator’s judgment.
23.The subject has active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before the baseline visit, or superficial skin infections within 1 week before the baseline visit.
Note: Patients with resolved infection may be rescreened.
24.The subject has history of malignancy within 5 years before the screening period, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin.
25.The subject has planned or anticipated the use of any prohibited medications and procedures during the entire study period.
26.The subject has planned or anticipated major surgical procedure during the entire study period.
27.High risk of parasite infection. Evidence of parasitic infection designated as having the following two items:
•Risk factors for parasitic disease include living in an endemic area, experiencing chronic gastrointestinal symptoms, traveling to regions where geohelminthic infections are endemic within the last 6 months, and/or having chronic immunosuppression).
AND
•Evidence of parasitic colonization or infection found during stool evaluation for ova and parasites.
Note: stool ova and parasite evaluation will only be conducted in patients with risk factors and an eosinophil count more than twice the upper limit of normal.
試驗計畫預計收納受試者人數
-
台灣人數
63 人
-
全球人數
90 人
